In the past year, the detection and characterization of fluid-based biomarkers in oncology witnessed an unprecedented level of progress, investment and industry partnership announcements. However, as the liquid assay landscape matures and the level of sensitivity and selectivity achieved by assays creates excitement for precision drug development, there remains a number of unique hurdles to translate rapid technical advancements towards the development of more effective and accessible precision oncology treatments.

That’s why the 6^th Liquid Biopsy for Precision Oncology Summit took place digitally in February, providing you with a valuable industry touchpoint to network, collaborate and learn directly from your peers at an exciting time for precision medicine.

As industry’s most comprehensive liquid biopsy meeting, uniting 600 key decision makers including Pfizer, AstraZeneca, Mirati Therapeutics, Kura Oncology, GSK, BloodPAC, International Society of Liquid Biopsy, Guardant Health, Natera and many more to address the key scientific, technical, regulatory, commercial and testing access challenges associated with progressing precision oncology pipelines harnessing liquid biopsy technology.

Exploring how a breadth of methods including ddPCR, single-cell genotypic & phenotypic analysis, in addition to pan-cancer, comprehensive NGS & tumor-informed assays are enabling detection screening, earlier diagnosis, resistance and recurrence monitoring – in turn facilitating quicker and more informed treatment decision-making in precision drug development.

Attendees joined to witness first-hand the clinical utility of ctDNA, cfDNA, miRNA & CTC analysis in the precision oncology pipelines of 30+ scientific & commercial biopharma & academic experts successfully advancing immunotherapy and targeted candidates toward patients.

A prime opportunity to meet diverse stakeholders and discover the most cutting-edge scientific data to strengthen your pipeline and capitalize on the vast amount of progress the field is witnessing.

A crucial annual date on the precision oncology’s industry calendar – It’s not to be missed!